In addition to inhibiting BCL2, navitoclax also inhibits its family members Bcl-xL and Bcl-w, which may add to the toxicity for HNSCC patients, reducing its clinical utility [8]. This evidence concerns the gene BCL2L1 and head and neck squamous cell carcinoma.